A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma

Gynecologic Oncology

Volumn 96, Issue 2, 2005, Pages 296-300

  Rose, Peter G ^a,b   Smrekar, Mary ^a,b   Fusco, Nancy ^c  

^a METROHEALTH MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Carboplatin; Carcinoma; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG RESPONSE; EVALUATION; FEMALE; FEVER; HOSPITALIZATION; HUMAN; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS;

EID: 12344276384     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.046     Document Type: Article

References (28)

1. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6
2. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92:2000;699-708
3. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 18:2000;2349-2351
4. Ozols R.F., Bundy B.N., Greer B.E., Fowler J., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21:2003;3194-3200
5. DuBois A, Lueck HJ, Meier W, Moebus V, Costa SD, Bauknecht T, et-al., AGO Ovarian Cancer Study Group, Dept. Gynecology St. Vincentius KHS, Karlsruhe, Germany. Proc ASCO 1999;18:356a.
6. International Collaborative Ovarian Neoplasm Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial. Lancet. 360:2002;505-515
7. Markman M., Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J. Clin. Oncol. 10:1992;513-514
8. Cantu M.G., Buda A., Parma G., Rossi R., Floriani I., Bonazzi C., et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J. Clin. Oncol. 20:2002;1232-1237
9. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12:1994;1748-1753
10. Zanotti K.M., Belinson J.L., Kennedy A.W., Webster K.D., Markman M. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol. Oncol. 79:2000;211-215
11. Dizon D.S., Hensley M.L., Poynor E.A., Sabbatini P., Aghajanian C., Hummer A., et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J. Clin. Oncol. 20:2002;1238-12347
12. Gronlund B., Hogdall C., Hansen H.H., Engleholm S.A. Results of re-induction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83:2001;128-134
13. Rose P.G., Fusco N., Fluellen L., Rodriguez M. Second-line therapy with paclitaxel and platinum for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16:1998;1494-1497
14. Ozols R.F. Recurrent ovarian cancer: evidence-based treatment. J. Clin. Oncol. 20:2002;1161-1163
15. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 361:2003;2099-2106
16. Anderson H, Bowman K, Ridderheim M, Rosenberg P, Sorbe B, Puistola U, et-al., Sahlgrenska Hospital, Gothenburg, Sweeden. Proc ASCO 2000;19:380a.
17. Markman M., Hall J., Spitz D., Weiner S., Carson L., Van Le L., et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel- refractory ovarian cancer. J. Clin. Oncol. 20:2002;2365-2369
18. Rustin G.J.S., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14:1996;1545-1551
19. Havrilesky L.J., Alvarez A.A., Sayer R.A., Lancaster J.M., Soper J.T., Berchuk A., et al. Weekly low dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol. Oncol. 88:2003;51-57
20. Dunton C.J. Phase II study of weekly paclitaxel and weekly carboplatinum in recurrent platinum sensitive ovarian cancer. Proc. ASCO. 22:2003;467a
21. Guminski A.D., Harnett P.R., deFazio A. Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - A potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother. Pharmacol. 48:2001;229-234
22. Pertusini E., Ratajczak J., Majka M., Vaughn D., Ratajczak M.Z., Gewirtz A.M. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood. 97:2001;638-644
23. Fujiwara K., Yamauchi H., Suzuki S., Ishikawa H., Tanaka Y., Fujiwara M., et al. The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. Cancer Chemother. Pharmacol. 47:2001;22-26
24. Ishikawa H., Fujiwara K., Suzuki S., Tanaka Y., Kohno I. Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients. Int. J. Clin. Oncol. 7:2002;330-333
25. Akerley W., Rathore R., Ready N., Leone L., Sikov W., Safran H., et al. A Phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer. 95:2002;2000-2005
26. Belani C.P. Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin. Oncol. 28:2001;14-16
27. Yu D.Y., Dahl G.V.H., Shames R.S., Fisher P.G. Weekly dosing of carboplatin increases risk of allergy in children. J. Pediatr. Hematol./Oncol. 23:2001;349-352
28. Sehouli J., et al. Ovarian Cancer Study group of the Nordostdeutsche Gesellschaft fur Gynakologische Onkologie (NOGGO) First line-chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Gynecol. Oncol. 85:2002;321-326